Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Soluble Triggering Receptor Expressed on Myeloid Cells 1 in lung cancer.

Kuemmel A, Alflen A, Schmidt LH, Sebastian M, Wiewrodt R, Schulze AB, Buhl R, Radsak M.

Sci Rep. 2018 Jul 17;8(1):10766. doi: 10.1038/s41598-018-28971-0.

2.

Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer.

Mikesch JH, Schwammbach D, Hartmann W, Schmidt LH, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoennissen NH, Wardelmann E, Köhler G, Lenz G, Müller-Tidow C, Berdel WE, Arteaga MF.

Eur Respir J. 2018 Jul 11;52(1). pii: 1701637. doi: 10.1183/13993003.01637-2017. Print 2018 Jul.

PMID:
29853494
3.

[Updated Recommendation for Treatment of Metastatic Non-Small Cell Lung Cancer].

Reinmuth N, Gröschel A, Schumann C, Sebastian M, Wiewrodt R, Reck M.

Pneumologie. 2018 Feb;72(2):138-154. doi: 10.1055/s-0043-118904. Epub 2017 Dec 21. German.

PMID:
29270953
4.

Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.

Schmidt LH, Heitkötter B, Schulze AB, Schliemann C, Steinestel K, Trautmann M, Marra A, Hillejan L, Mohr M, Evers G, Wardelmann E, Rahbar K, Görlich D, Lenz G, Berdel WE, Hartmann W, Wiewrodt R, Huss S.

PLoS One. 2017 Oct 27;12(10):e0186280. doi: 10.1371/journal.pone.0186280. eCollection 2017.

5.

Individualisierte Therapie des metastasierten Lungenkarzinoms.

Evers G, Mohr M, Kerkhoff A, Lenz G, Wiewrodt R, Schmidt LH.

Dtsch Med Wochenschr. 2017 Oct;142(20):1531-1534. doi: 10.1055/s-0043-103471. Epub 2017 Oct 10. German.

PMID:
29017211
6.

Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W.

PLoS One. 2017 Aug 9;12(8):e0183201. doi: 10.1371/journal.pone.0183201. eCollection 2017.

7.

Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W.

PLoS One. 2017 Jun 12;12(6):e0177146. doi: 10.1371/journal.pone.0177146. eCollection 2017. Erratum in: PLoS One. 2017 Aug 9;12 (8):e0183201.

8.

Rhesus CE expression on patient red blood cells is an independent prognostic factor for adenocarcinoma of the lung.

Schulze AB, Schmidt LH, Baie L, Heitkötter B, Kuemmel A, Mohr M, Buhl R, Hillmann H, Geißler G, Kelsch R, Görlich D, Berdel WE, Hartmann W, Wiewrodt R.

Clin Respir J. 2018 Mar;12(3):1106-1117. doi: 10.1111/crj.12638. Epub 2017 Apr 26.

PMID:
28398662
9.

Progressive histoplasmosis with hemophagocytic lymphohistiocytosis and epithelioid cell granulomatosis: A case report and review of the literature.

Schulze AB, Heptner B, Kessler T, Baumgarten B, Stoica V, Mohr M, Wiewrodt R, Warneke VS, Hartmann W, Wüllenweber J, Schülke C, Schäfers M, Wilmes D, Becker K, Schmidt LH, Groll AH, Berdel WE.

Eur J Haematol. 2017 Jul;99(1):91-100. doi: 10.1111/ejh.12886. Epub 2017 May 11. Review.

PMID:
28349614
10.

IL-17C mediates the recruitment of tumor-associated neutrophils and lung tumor growth.

Jungnickel C, Schmidt LH, Bittigkoffer L, Wolf L, Wolf A, Ritzmann F, Kamyschnikow A, Herr C, Menger MD, Spieker T, Wiewrodt R, Bals R, Beisswenger C.

Oncogene. 2017 Jul 20;36(29):4182-4190. doi: 10.1038/onc.2017.28. Epub 2017 Mar 27.

PMID:
28346430
11.

Nontypeable Haemophilus influenzae-Promoted Proliferation of Kras-Induced Early Adenomatous Lesions Is Completely Dependent on Toll-Like Receptor Signaling.

Jungnickel C, Schnabel PA, Bohle R, Wiewrodt R, Herr C, Bals R, Beisswenger C.

Am J Pathol. 2017 May;187(5):973-979. doi: 10.1016/j.ajpath.2017.01.003. Epub 2017 Mar 6.

PMID:
28279655
12.

[Therapy of Metastatic Non-small Cell Lung Cancer].

Reinmuth N, Gröschel A, Schumann C, Sebastian M, Wiewrodt R, Reck M.

Pneumologie. 2016 Sep;70(9):567-78. doi: 10.1055/s-0042-113087. Epub 2016 Sep 7. Review. German.

PMID:
27603945
13.

Thoracic Malignancies and Pulmonary Nodules in Patients under Evaluation for Transcatheter Aortic Valve Implantation (TAVI): Incidence, Follow Up and Possible Impact on Treatment Decision.

Schmidt LH, Vietmeier B, Kaleschke G, Schülke C, Görlich D, Schliemann C, Kessler T, Schulze AB, Buerke B, Kuemmel A, Thrull M, Wiewrodt R, Baumgartner H, Berdel WE, Mohr M.

PLoS One. 2016 May 12;11(5):e0155398. doi: 10.1371/journal.pone.0155398. eCollection 2016.

14.

Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC.

Schmidt LH, Kuemmel A, Schliemann C, Schulze A, Humberg J, Mohr M, Görlich D, Hartmann W, Bröckling S, Marra A, Hillejan L, Goletz S, Karsten U, Berdel WE, Spieker T, Wiewrodt R.

Lung Cancer. 2016 Feb;92:8-14. doi: 10.1016/j.lungcan.2015.11.019. Epub 2015 Nov 27.

PMID:
26775589
15.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.

Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators.

Ann Oncol. 2016 Mar;27(3):417-23. doi: 10.1093/annonc/mdv597. Epub 2015 Dec 8.

16.

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.

Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, Grünewald I, Marra A, Schultheis AM, Wardelmann E, Müller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W.

PLoS One. 2015 Aug 27;10(8):e0136023. doi: 10.1371/journal.pone.0136023. eCollection 2015.

17.

Epigenetic dysregulation of KCa 3.1 channels induces poor prognosis in lung cancer.

Bulk E, Ay AS, Hammadi M, Ouadid-Ahidouch H, Schelhaas S, Hascher A, Rohde C, Thoennissen NH, Wiewrodt R, Schmidt E, Marra A, Hillejan L, Jacobs AH, Klein HU, Dugas M, Berdel WE, Müller-Tidow C, Schwab A.

Int J Cancer. 2015 Sep 15;137(6):1306-17. doi: 10.1002/ijc.29490. Epub 2015 May 29.

18.

Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis.

Mohr M, Schliemann C, Biermann C, Schmidt LH, Kessler T, Schmidt J, Wiebe K, Müller KM, Hoffmann TK, Groll AH, Werner C, Kessler C, Wiewrodt R, Rudack C, Berdel WE.

Oncol Lett. 2014 Nov;8(5):1912-1918. Epub 2014 Aug 28.

19.

Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.

Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, Serke M, Stöhlmacher-Williams J, Märten A, Maria Huber R, Dickgreber NJ; Afatinib Compassionate Use Consortium (ACUC).

J Thorac Oncol. 2015 Jan;10(1):156-63. doi: 10.1097/JTO.0000000000000380.

20.

Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancer.

Schmidt LH, Görlich D, Spieker T, Rohde C, Schuler M, Mohr M, Humberg J, Sauer T, Thoenissen NH, Huge A, Voss R, Marra A, Faldum A, Müller-Tidow C, Berdel WE, Wiewrodt R.

J Thorac Oncol. 2014 Sep;9(9):1294-304. doi: 10.1097/JTO.0000000000000243.

21.

The European initiative for quality management in lung cancer care.

Blum TG, Rich A, Baldwin D, Beckett P, De Ruysscher D, Faivre-Finn C, Gaga M, Gamarra F, Grigoriu B, Hansen NC, Hubbard R, Huber RM, Jakobsen E, Jovanovic D, Konsoulova A, Kollmeier J, Massard G, McPhelim J, Meert AP, Milroy R, Paesmans M, Peake M, Putora PM, Scherpereel A, Schönfeld N, Sitter H, Skaug K, Spiro S, Strand TE, Taright S, Thomas M, van Schil PE, Vansteenkiste JF, Wiewrodt R, Sculier JP.

Eur Respir J. 2014 May;43(5):1254-77. doi: 10.1183/09031936.00106913. Epub 2014 Mar 23.

22.

DNA methyltransferase inhibition reverses epigenetically embedded phenotypes in lung cancer preferentially affecting polycomb target genes.

Hascher A, Haase AK, Hebestreit K, Rohde C, Klein HU, Rius M, Jungen D, Witten A, Stoll M, Schulze I, Ogawa S, Wiewrodt R, Tickenbrock L, Berdel WE, Dugas M, Thoennissen NH, Müller-Tidow C.

Clin Cancer Res. 2014 Feb 15;20(4):814-26. doi: 10.1158/1078-0432.CCR-13-1483. Epub 2013 Dec 13.

23.

[Employing tyrosine kinase inhibitors in the first line treatment of EGFR-positive metastatic NSCLC - state of the art and recent developments].

Wiewrodt R, Serke M, Grohé C, Brückl W.

Pneumologie. 2013 Sep;67(9):494-501. doi: 10.1055/s-0033-1344337. Epub 2013 Sep 4. Review. German.

24.

Myeloid cell RelA/p65 promotes lung cancer proliferation through Wnt/β-catenin signaling in murine and human tumor cells.

Li D, Beisswenger C, Herr C, Hellberg J, Han G, Zakharkina T, Voss M, Wiewrodt R, Bohle RM, Menger MD, Schmid RM, Stöckel D, Lenhof HP, Bals R.

Oncogene. 2014 Mar 6;33(10):1239-48. doi: 10.1038/onc.2013.75. Epub 2013 Apr 8.

PMID:
23563178
25.

Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer.

Bulk E, Yu J, Hascher A, Koschmieder S, Wiewrodt R, Krug U, Timmermann B, Marra A, Hillejan L, Wiebe K, Berdel WE, Schwab A, Müller-Tidow C.

PLoS One. 2012;7(12):e44591. doi: 10.1371/journal.pone.0044591. Epub 2012 Dec 4.

26.

Non-invasive ventilation in immunosuppressed patients with pneumonia and extrapulmonary sepsis.

Razlaf P, Pabst D, Mohr M, Kessler T, Wiewrodt R, Stelljes M, Reinecke H, Waltenberger J, Berdel WE, Lebiedz P.

Respir Med. 2012 Nov;106(11):1509-16. doi: 10.1016/j.rmed.2012.08.007. Epub 2012 Sep 1.

27.

The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth.

Schmidt LH, Spieker T, Koschmieder S, Schäffers S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D, Marra A, Hillejan L, Wiebe K, Berdel WE, Wiewrodt R, Muller-Tidow C.

J Thorac Oncol. 2011 Dec;6(12):1984-92. doi: 10.1097/JTO.0b013e3182307eac. Erratum in: J Thorac Oncol. 2012 Jul;7(7):1206. Schäffers, Sonja [added].

28.

[Thoracic oncology].

Schmidt LH, Mohr M, Wiewrodt R.

Dtsch Med Wochenschr. 2011 Oct;136(40):2029-32. doi: 10.1055/s-0031-1286387. Epub 2011 Sep 28. Review. German. No abstract available.

PMID:
21960333
29.

Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancer.

Becker S, Markova B, Wiewrodt R, Hoffarth S, Hähnel PS, Pleiner S, Schmidt LH, Breitenbuecher F, Schuler M.

J Thorac Oncol. 2011 Dec;6(12):1976-83. doi: 10.1097/JTO.0b013e31822e59dd.

30.

Targeted endothelial delivery of nanosized catalase immunoconjugates protects lung grafts donated after cardiac death.

Preissler G, Loehe F, Huff IV, Ebersberger U, Shuvaev VV, Bittmann I, Hermanns I, Kirkpatrick JC, Fischer K, Eichhorn ME, Winter H, Jauch KW, Albelda SM, Muzykantov VR, Wiewrodt R.

Transplantation. 2011 Aug 27;92(4):380-7. doi: 10.1097/TP.0b013e318226bc6b.

31.

Pulmonary dirofilariasis in a Caucasian patient with metastasised osteosarcoma in a non-endemic European region.

Schmidt LH, Dirksen U, Reiter-Owona I, Khurana C, Wiebe K, Wiewrodt R, Spieker T.

Thorax. 2011 Mar;66(3):270. doi: 10.1136/thx.2010.142323. Epub 2010 Nov 15. No abstract available.

PMID:
21081486
32.

Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissue.

Schmidt LH, Biesterfeld S, Kümmel A, Faldum A, Sebastian M, Taube C, Buhll R, Wiewrodt R.

Anticancer Res. 2009 Jan;29(1):201-9.

33.

A key regulatory role of the transcription factor NFATc2 in bronchial adenocarcinoma via CD8+ T lymphocytes.

Maxeiner JH, Karwot R, Sauer K, Scholtes P, Boross I, Koslowski M, Türeci O, Wiewrodt R, Neurath MF, Lehr HA, Finotto S.

Cancer Res. 2009 Apr 1;69(7):3069-76. doi: 10.1158/0008-5472.CAN-08-1678. Epub 2009 Mar 24.

34.

Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.

Sebastian M, Kiewe P, Schuette W, Brust D, Peschel C, Schneller F, Rühle KH, Nilius G, Ewert R, Lodziewski S, Passlick B, Sienel W, Wiewrodt R, Jäger M, Lindhofer H, Friccius-Quecke H, Schmittel A.

J Immunother. 2009 Feb-Mar;32(2):195-202. doi: 10.1097/CJI.0b013e318195b5bb.

PMID:
19238019
35.

[Hemorrhagic pericardial effusion and multiple pulmonary nodules in a 37 year old male who has "never smoked"].

Sebastian M, Schad A, Schadmand-Fischer S, Post F, Meier S, Springer E, Makowski J, Taube C, Wiewrodt R, Fischer B, Buhl R.

Internist (Berl). 2009 Jan;50(1):91-4. doi: 10.1007/s00108-008-2239-0. German.

PMID:
18979079
36.

TA-MUC1 epitope in non-small cell lung cancer.

Kuemmel A, Single K, Bittinger F, Faldum A, Schmidt LH, Sebastian M, Micke P, Taube C, Buhl R, Wiewrodt R.

Lung Cancer. 2009 Jan;63(1):98-105. doi: 10.1016/j.lungcan.2008.04.005. Epub 2008 Jun 9.

PMID:
18539357
37.

The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer.

Kuemmel A, Single K, Bittinger F, Faldum A, Schmidt LH, Sebastian M, Taube C, Buhl R, Wiewrodt R.

Tumour Biol. 2007;28(6):340-9. doi: 10.1159/000124298. Epub 2008 Apr 4.

PMID:
18391551
38.

Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease.

Radsak MP, Taube C, Haselmayer P, Tenzer S, Salih HR, Wiewrodt R, Buhl R, Schild H.

Clin Dev Immunol. 2007;2007:52040. doi: 10.1155/2007/52040.

39.

Mast cell-derived tumour necrosis factor is essential for allergic airway disease.

Reuter S, Heinz A, Sieren M, Wiewrodt R, Gelfand EW, Stassen M, Buhl R, Taube C.

Eur Respir J. 2008 Apr;31(4):773-82. Epub 2007 Dec 19.

40.

pp32/PHAPI determines the apoptosis response of non-small-cell lung cancer.

Hoffarth S, Zitzer A, Wiewrodt R, Hähnel PS, Beyer V, Kreft A, Biesterfeld S, Schuler M.

Cell Death Differ. 2008 Jan;15(1):161-70. Epub 2007 Oct 26.

41.

Autoantibodies in lung cancer: possibilities for early detection and subsequent cure.

Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Türeci O, Wiewrodt R, Barnes AC, Robertson JF.

Thorax. 2008 Mar;63(3):228-33. Epub 2007 Oct 11. Erratum in: Thorax. 2008 Apr;63(4):385.

PMID:
17932110
42.

The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells.

von Haussen J, Koczulla R, Shaykhiev R, Herr C, Pinkenburg O, Reimer D, Wiewrodt R, Biesterfeld S, Aigner A, Czubayko F, Bals R.

Lung Cancer. 2008 Jan;59(1):12-23. Epub 2007 Aug 31.

PMID:
17764778
43.

Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.

Wesarg E, Hoffarth S, Wiewrodt R, Kröll M, Biesterfeld S, Huber C, Schuler M.

Int J Cancer. 2007 Dec 1;121(11):2387-94.

44.

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.

Sebastian M, Passlick B, Friccius-Quecke H, Jäger M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A.

Cancer Immunol Immunother. 2007 Oct;56(10):1637-44. Epub 2007 Apr 5.

PMID:
17410361
45.

c-kit expression in adenocarcinomas of the lung.

Micke P, Hengstler JG, Albrecht H, Faldum A, Bittinger F, Becker K, Wiewrodt R, Fischer B, Buhl R.

Tumour Biol. 2004 Sep-Dec;25(5-6):235-42.

PMID:
15627886
46.

Characterization of the interstitial lung and peripheral blood T cell receptor repertoire in cigarette smokers.

Korn S, Wiewrodt R, Walz YC, Becker K, Mayer E, Krummenauer F, Buhl R.

Am J Respir Cell Mol Biol. 2005 Feb;32(2):142-8. Epub 2004 Nov 11.

PMID:
15539458
47.
48.

Gene expression profiling of malignant mesothelioma.

Singhal S, Wiewrodt R, Malden LD, Amin KM, Matzie K, Friedberg J, Kucharczuk JC, Litzky LA, Johnson SW, Kaiser LR, Albelda SM.

Clin Cancer Res. 2003 Aug 1;9(8):3080-97.

49.

PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress.

Christofidou-Solomidou M, Scherpereel A, Wiewrodt R, Ng K, Sweitzer T, Arguiri E, Shuvaev V, Solomides CC, Albelda SM, Muzykantov VR.

Am J Physiol Lung Cell Mol Physiol. 2003 Aug;285(2):L283-92.

50.

Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.

Wiewrodt R, Amin K, Kiefer M, Jovanovic VP, Kapoor V, Force S, Chang M, Lanuti M, Black ME, Kaiser LR, Albelda SM.

Cancer Gene Ther. 2003 May;10(5):353-64.

PMID:
12719705

Supplemental Content

Loading ...
Support Center